News

Pharm-Olam Experts to Present Live Seminar on Evolution of Response Evaluation in Oncology Trials

Thursday, March 23, 2017

Global clinical research experts Yamin “Mo” Khan, PhD, and Dhiraj Abhyankar, MD will host an interactive discussion and seminar on the Evolution of Response Evaluation in Oncology Trials. The free public forum will be held at 11 a.m. Eastern Standard Time on Thursday, March 30 via webinar.

Global CRO Pharm-Olam International Announces New Addition to Lead Biostatistics Team

Wednesday, February 22, 2017

HOUSTON, TEXAS – Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Julia Graz as Senior Director, Biostatistics.

Quad-C Management Announces Investment in Pharm-Olam International

Thursday, February 9, 2017

Charlottesville, VA. – Quad-C Management, Inc. (“Quad-C”), a leading middle market private equity firm, today announced it has closed an investment in Pharm-Olam International Ltd., a multinational, full-service clinical research organization (CRO), serving the biopharmaceutical and medical device industries. Terms of the transaction were not disclosed.

Pharm-Olam International Deploys Medidata Rave; Shores up Global Data Management and Reporting Capabilities

Tuesday, January 31, 2017

HOUSTON, TEXAS – January 31, 2017. Pharm-Olam International Ltd., a multinational, full-service clinical research organization (CRO) serving the biopharmaceutical and medical device industries, today announced that it has deployed Medidata Rave®—the industry’s leading electronic data capture (EDC), management and reporting tool—to streamline its global Data Management and Reporting services.

Global CRO Pharm-Olam International Announces New Addition to the Quality and Compliance Leadership Team

Wednesday, November 16, 2016

Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Daniel Burgess to the position of Senior Director, Quality and Compliance. 

Global Clinical Research Thought Leaders to Address Rescue Study Challenges in Upcoming Live Seminar

Tuesday, November 1, 2016

Global clinical research experts Yamin “Mo” Khan, Ph.D., and Oleksandr Iaroshkevych, M.D., Ph.D. will host an interactive public seminar on the implications of failing or stalled clinical trials. The forum, entitled, “The Do’s and Don’ts of Study Transfer,” will be held at 11 a.m. on Thursday, November 10 via webinar.

Pharm-Olam Adds Director of Scientific Development, Strengthens Oncology Capabilities

Tuesday, October 25, 2016

Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Dr. Dhiraj Abhyankar to the position of Director, Scientific Development. 

Pharm-Olam International Nominated for Best Full-Service CRO in 2016 Scrip Awards

Tuesday, September 27, 2016

Pharm-Olam International is proud to announce that it has been named a finalist in the 2016 Scrip Awards in the category of Best Contract Research Organization – Full-Service Providers. The nomination comes as a result of Pharm-Olam’s strong showing against a competitive field of other midsize and global CRO competitors.

Pharm-Olam International Selected as 37th Annual Telly Award Winner for Promotion of Allergy and Asthma Clinical Research

Thursday, September 1, 2016

The 37th Annual Telly Awards has named Pharm-Olam International as a winner for its Allergy Studies Online Video. A prestigious judging panel selected Pharm-Olam’s video from a competitive pool of over 13,000 entries from all 50 states and numerous countries.

Pharm-Olam International Bolsters Client Outreach with Strategic Hire in Proposals and Contracts

Wednesday, August 17, 2016

Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO), serving the biopharmaceutical and medical device industries, announces the appointment of David Murcar to the position of Director, Proposals and Contracts.